Ensuring genomic stability in human iPSC cultures for clinical applications
Background
Human induced pluripotent stem cells (hiPSCs) are becoming increasingly important for regenerative medicine and cell therapy, placing greater emphasis on maintaining their genomic integrity throughout manufacturing. During reprogramming and prolonged culture, hiPSCs can gradually acquire genetic alterations that may affect differentiation potential or introduce safety concerns for clinical applications. Although routine quality control methods remain essential, they often fail to detect smaller genomic changes that accumulate over time, highlighting the need for more comprehensive approaches to evaluating genetic stability.
Biolaminin® contribution
Zhang et al. investigated genomic stability in three clinical grade hiPSC lines over 50 passages to understand how genetic integrity changes during prolonged culture. The study followed cell lines generated under defined, clinically relevant culture conditions, including Biolaminin 521 during early close selection and expansion, before evaluating genomic stability throughout long-term culture.
Rather than relying on a single quality control assay, the researchers evaluated each cell line using complementary genomic analyses that examined genetic stability from different perspectives. This approach resealed that genomic alterations accumulated progressively with continued passaging, while also demonstrating that no individual method detected every clinically relevant abnormality. Some alterations were only identified when multiple datasets were considered together, providing a more complete understanding of how genomic integrity changed during long-term culture.
Importantly, the detected genomic changes were not limited to structural alterations alone. As cultures acquired recurrent genomic abnormalities, corresponding changes in gene expression were also observed, including genes associated with cell proliferation and tumorigenesis. These findings emphasize that evaluating genomic stability requires understanding not only whether genetic alterations are present, but also how those alterations may influence cellular behavior during continued expansion.
Future outlook
Quality control becomes increasingly important as human iPSC-derived products progress toward clinical use. Instead of viewing genomic stability as a single release test, this study proposes a broader strategy in which genetic integrity is monitored throughout clone selection, cell banking, and long-term expansion. By integrating complementary genomic analyses within a defined manufacturing workflow, the authors provide a practical framework for supporting the safe development of future hiPSC-derived therapies.
Talk to our team for customized support
We are here to help you in your journey.